Impact of curative ablation on pharmacologic management in children with reentrant supraventricular tachycardias

Int J Cardiol. 2004 Apr;94(2-3):279-82. doi: 10.1016/j.ijcard.2003.05.023.

Abstract

Background: The introduction of radiofrequency catheter ablation as a curative treatment option has led to a much better outlook for children with recurrent supraventricular reentrant tachycardias (SVT). This study sought to evaluate the impact of ablation on pharmacologic treatment of SVT.

Methods: Two time periods were retrospectively compared with regard to number of episodes of SVT in different age groups, number of acute drug conversions of SVT, chronic antiarrhythmic drug treatments prescribed: in the first period (1989-1994) management of SVT was exclusively pharmacological whereas during the second period (1995-2000) ablation was an option for patients aged 5 years or older.

Results: The study included 88 pediatric patients with recurrent SVT, 40 in the first period, 48 in the latter. Of these, 16 children (all >5 years of age) had an ablation procedure during the second time period. In patients aged >5 years, the number of documented SVT fell from a mean of 3.7/patient to two episodes. The number of acute drug conversions of SVT decreased from a mean of 1.1/patient to 0.2 (p<0.05) during the second period. In the group of children aged >5 years chronic antiarrhythmic treatment was given during a mean of 15 months/patient in period one compared to 4.6 months (p<0.05) in the second period.

Conclusion: In the current era with increasing use of ablation as first-line treatment in older children with recurrent SVT, acute as well as chronic pharmacologic intervention for SVT has become significantly less frequent.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Anti-Arrhythmia Agents / therapeutic use*
  • Catheter Ablation / methods*
  • Child
  • Child, Preschool
  • Humans
  • Recurrence
  • Retrospective Studies
  • Tachycardia, Supraventricular / drug therapy*
  • Tachycardia, Supraventricular / therapy*
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents